Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2016 - 2018)

Catalyst Pharmaceuticals' Current Deferred Revenue history spans 7 years, with the latest figure at $33408.0 for Q4 2018.

  • For Q4 2018, Current Deferred Revenue rose 39.14% year-over-year to $33408.0; the TTM value through Dec 2018 reached $33408.0, up 39.14%, while the annual FY2018 figure was $33408.0, 39.14% up from the prior year.
  • Current Deferred Revenue reached $33408.0 in Q4 2018 per CPRX's latest filing, up from $21914.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $33408.0 in Q4 2018 to a low of $3254.0 in Q1 2014.
  • Average Current Deferred Revenue over 5 years is $16181.7, with a median of $18094.0 recorded in 2016.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 335.14% in 2015, then fell 2.27% in 2018.
  • A 5-year view of Current Deferred Revenue shows it stood at $4158.0 in 2014, then surged by 335.14% to $18093.0 in 2015, then rose by 0.01% to $18094.0 in 2016, then skyrocketed by 32.7% to $24011.0 in 2017, then soared by 39.14% to $33408.0 in 2018.
  • Per Business Quant, the three most recent readings for CPRX's Current Deferred Revenue are $33408.0 (Q4 2018), $21914.0 (Q3 2018), and $27184.0 (Q2 2018).